Immunosuppressive Therapy

Fillmore has investigated the impact of immunosuppressive therapies on vaccine efficacy and clinical outcomes during SARS-CoV-2 infections. His research demonstrates that patients receiving antineoplastic agents, solid organ transplant medications, and treatments for plasma cell disorders face a significantly higher risk of breakthrough infections and severe disease despite vaccination. These findings underscore the necessity of booster doses and oral antiviral therapies to mitigate morbidity in immunocompromised populations.